Lenvatinib Mesylate

DRUG6 trials

Sponsors

Floor Backes, Academic and Community Cancer Research United, Emory University, Shanghai Jiahui International Hospital, City of Hope Medical Center

Conditions

Advanced Biliary Tract CarcinomaAdvanced Pancreatic Ductal AdenocarcinomaClinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8

Phase 1

Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer

CompletedNCT02788708

Floor BackesFallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Endometrial Cancer +1

Start: 2016-05-27End: 2022-03-31Updated: 2022-09-19

Phase 2

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

CompletedNCT02973997

Academic and Community Cancer Research UnitedColumnar Cell Variant Thyroid Gland Papillary Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma, Metastatic Thyroid Gland Follicular Carcinoma +23

Start: 2018-02-07End: 2023-10-08Updated: 2025-08-29

Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma

Active, not recruitingNCT04393350

Emory UniversityKidney Cancer, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8

Start: 2020-06-22End: 2026-01-16Updated: 2025-02-26

Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract Carcinoma

CompletedNCT04550624

Shanghai Jiahui International HospitalAdvanced Biliary Tract Carcinoma

Start: 2021-09-15End: 2025-12-02Updated: 2026-01-21

Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer

RecruitingNCT04887805

City of Hope Medical CenterAdvanced Pancreatic Ductal Adenocarcinoma, Stage IIA Pancreatic Cancer AJCC v8, Stage IIB Pancreatic Cancer AJCC v8 +4

Start: 2021-07-21End: 2026-11-05Target: 28Updated: 2025-11-19

Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer

Active, not recruitingNCT04929392

City of Hope Medical CenterClinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8 +16

Start: 2022-01-25End: 2027-04-25Updated: 2025-09-04

Related Papers

Abstract A015: Phase II trial of perioperative Lenvatinib plus Pembrolizumab in locally advanced nonmetastatic clear cell renal cell carcinoma

Cancer Research2026-03-13

Phase 2 study of perioperative lenvatinib (L) with pembrolizumab (P) in patients with locally advanced nonmetastatic clear cell renal cell carcinoma.

Journal of Clinical Oncology2025-02-101 citations

Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma.

2023-05-1037 citations

Lenvatinib plus pembrolizumab combination therapy in patients with radioiodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC): Results of a multicenter phase II international thyroid oncology group trial.

Journal of Clinical Oncology2020-05-2044 citations